Terui Yasuhito
Nihon Rinsho. 2015 Jan;73(1):124-9.
Epigenetic abnormalities are central players in the disruption of common cancer pathway, and epigenetic aberrations have also been shown to play an important role in development of multiple myeloma. DNA methylation, histone modifications contribute to the pathogenesis of multiple myeloma. Understanding of epigenetic abnormalities in myeloma leads to development of novel drugs such as histone deacetylase inhibitors (HDACi). Here I will discuss about common epigenetic mechanisms (aberrant DNA methylation, histone modifications), the epigenetic aberrations in myeloma and clinical development of novel drug HDACi.
表观遗传异常是常见癌症通路破坏的核心因素，并且表观遗传畸变在多发性骨髓瘤的发生发展中也发挥着重要作用。DNA甲基化、组蛋白修饰参与了多发性骨髓瘤的发病机制。对骨髓瘤表观遗传异常的了解促使了诸如组蛋白去乙酰化酶抑制剂（HDACi）等新型药物的研发。在此，我将讨论常见的表观遗传机制（异常DNA甲基化、组蛋白修饰）、骨髓瘤中的表观遗传畸变以及新型药物HDACi的临床进展。
